Sun’s Indian Nilotinib Plans Blocked By Novartis
Firms Battle Over Tasigna Intellectual Property
Executive Summary
Novartis thwarts Sun’s efforts to commercialize nilotinib in India, though the Indian firm indicates that its actions are covered under a local Bolar-type provision and that it has no plans to market the oncology drug while the originator's patent stands valid.